Ernexa Therapeutics (NASDAQ:ERNA) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Ernexa Therapeutics (NASDAQ:ERNA) issued its earnings results on Thursday. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10), FiscalAI reports.

Ernexa Therapeutics Price Performance

ERNA stock traded up $0.26 during midday trading on Thursday, reaching $4.36. The company had a trading volume of 36,336 shares, compared to its average volume of 1,388,542. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $71.50. The stock has a 50 day moving average price of $6.00 and a 200-day moving average price of $8.88. The company has a market capitalization of $5.08 million, a price-to-earnings ratio of -0.17 and a beta of 2.57.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on ERNA shares. Wall Street Zen upgraded shares of Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Finally, Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ernexa Therapeutics presently has a consensus rating of “Hold” and an average price target of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.